Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling, Inc. generated company news around recycled metals processing, nonferrous and ferrous market conditions, finished steel operations, earnings releases, and operating initiatives in metal recovery and recycling services. Coverage also included governance changes and capital-structure matters tied to material agreements and shareholder actions.
In July 2025, Radius Recycling completed a merger and became a wholly owned subsidiary of Toyota Tsusho America, Inc. Subsequent RDUS-related developments center on the company's corporate-status transition, delisting and deregistration steps, and historical public-company disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Gurnet Point Capital and Patient Square Capital have successfully completed their acquisition of Radius Health (Nasdaq: RDUS) for $10.00 per share in cash, plus a contingent value right to receive an additional $1.00 if TYMLOS sales exceed $300 million by 2025. Radius, known for its lead product TYMLOS, which treats osteoporosis in postmenopausal women, will be delisted from NASDAQ following the merger. The acquisition aligns with the investors’ strategy to enhance operational efficiencies in healthcare.
The Menarini Group and Stemline Therapeutics announced that the FDA has accepted the New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD) for patients with ER+/HER2- advanced or metastatic breast cancer. The NDA, supported by the positive results of the Phase 3 EMERALD study, demonstrates elacestrant's significant efficacy over standard-of-care treatments. The FDA has assigned a PDUFA date of February 17, 2023, and granted Priority Review designation, indicating its potential to improve treatment options significantly.
The Menarini Group and Stemline Therapeutics announced the FDA's acceptance of the New Drug Application (NDA) for elacestrant, a potential treatment for ER+/HER2- advanced or metastatic breast cancer. The FDA has granted Priority Review with a PDUFA date of February 17, 2023. The NDA is supported by Phase 3 EMERALD study results, showing elacestrant's statistically significant efficacy over standard treatment, with a 30% reduced risk of progression in all patients and a 45% reduction in patients with ESR1 mutations. Elacestrant remains investigational and not yet FDA-approved.
Velan Capital Investment Management and Repertoire Partners, holding approximately 7.7% of Radius Health's outstanding shares, announced their withdrawal of director nominations following a proposed sale to Gurnet Point Capital and Patient Square Capital. They believe the sale price does not fully reflect the value of the company and its assets, but express satisfaction that their involvement may help stockholders recover some lost value under the current Board of Directors. They also thanked their qualified director candidates and supporters.
Radius Health, Inc. (Nasdaq: RDUS) encourages stockholders to vote 'FOR' their independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D., and Andrew C. von Eschenbach, M.D. – using the BLUE proxy card ahead of their Annual Meeting on July 26, 2022. The company also shared an investor presentation detailing its progress since 2020 and the board's unanimous approval of a significant acquisition by Gurnet Point Capital and Patient Square Capital, offering stockholders a premium on their shares.